Navigation Links
TNF Protein Can Predict GVHD Bone Marrow Transplant Recipients

The outcome of bone marrow transplant could be determined in just one week by measuring levels of a protein called tumor necrosis factor (TNF). // The inflammatory marker can help doctors identify which patients will develop graft vs. host disease (GVHD), the most commonly observed complication following the surgery.

The early identification of related complication can enable the attending physician to initiate appropriate preventive treatment. Bone marrow transplant is a life-saving treatment for children and adults with hematological malignancies and other similar blood or immune system disorders.

Bone marrow transplantation is a surgical procedure in which the patient's diseased bone marrow is replaced with a healthy one, derived from a donor. This enables high doses of chemotherapy to be directed to cancer cells. The possibility of the recipient's immune cells rejecting the new bone marrow poses a severe threat to the graft survival. The patient's skin, gastrointestinal and liver cells can be destroyed, sometimes, even leading to death.

The researchers studied the measurement of TNF levels in 170 patients, out of which 94 had established GVHD (the graft attacks the patient tissue). All these patients were found to have elevated levels of TNF levels, 1 week after their transplant. In addition, the patients had a poor survival rate (62%).

'This suggests we could target patients to prevent graft vs. host disease based on their post-transplant level of TNF. If we can develop a test that can reliably predict this complication, we can then look at treating it before any symptoms develop. This is one small step in a long road to making transplants safer and more effective,' said John Levine, study author.

'TNF is known to play a role in a variety of inflammatory or autoimmune diseases, including septic shock, rheumatoid arthritis and Crohn's disease. Anti-TNF drugs are already FDA-approved and available on the market. We are currently conducting a clinical trial using one of these drugs, etanercept, in clinical trials to see if it can prevent or treat GVHD,' concluded Dr. Carrie Kitko, yet another study author.


'"/>




Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
3. Unravelling the secrets of ‘Huntingtin’ Protein - towards the treatment of ‘Huntingtons’ Disase
4. Unravelling the secrets of ‘Huntingtin’ Protein - towards the treatment of Huntingtins’ Disese
5. Protein in urine foresees heart disease
6. Levels Of Blood Proteins May Help Heart Disease Care
7. Protein signals need for heart surgery
8. Protein and fat improve memory
9. Clotting Protein plays a role in nerve repair
10. High Levels of Protein Linked to Brain Shrinkage
11. Protein can change worn muscle fibres
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 /PRNewswire/ ... SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the ... by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) ... Novartis today announced that the data are being featured ... American Society of Hematology (ASH) Annual Meeting and ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: